---
title: "EOLS.US (EOLS.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/EOLS.US/news.md"
symbol: "EOLS.US"
name: "EOLS.US"
parent: "https://longbridge.com/en/quote/EOLS.US.md"
datetime: "2026-05-20T17:06:57.989Z"
locales:
  - [en](https://longbridge.com/en/quote/EOLS.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/EOLS.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/EOLS.US/news.md)
---

# EOLS.US (EOLS.US) — Related News

### [Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe](https://longbridge.com/en/news/285945546.md)
*2026-05-11T12:34:23.000Z*
> A global beauty company, Evolus, Inc. (NASDAQ: EOLS), based in Newport Beach, California, revealed its plan to launch Es

### [Evolus (EOLS) Breakeven Q4 EPS Tests Skeptics Of Its Profitability Path](https://longbridge.com/en/news/285353069.md)
*2026-05-06T10:08:30.000Z*
> Evolus (EOLS) reported Q4 2025 revenue of US$90.3 million and a basic EPS of approximately US$0.00, with a net income of

### [](https://longbridge.com/en/news/285231472.md)
*2026-05-05T15:02:52.000Z*
> Evolus shares are trading higher after the company reported better-than-expected Q1 sales results.

### [Evolus Maintains Buy Rating as Scalable Growth Story Solidifies; $13 Price Target Reaffirmed](https://longbridge.com/en/news/285188212.md)
*2026-05-05T10:35:25.000Z*
> Analyst Douglas Tsao of H.C. Wainwright has maintained a Buy rating on Evolus, reaffirming a price target of $13.00. Thi

### [Evolus Earnings Call Highlights Profitable Growth Path](https://longbridge.com/en/news/285138125.md)
*2026-05-05T00:26:55.000Z*
> Evolus, Inc. reported Q1 earnings with a 7% year-over-year revenue increase to $73.1 million, driven by its neurotoxin J

### [Evolus, Inc. 1Q 2026: Revenue $73.14M, EPS ($0.16) — 10-Q Summary](https://longbridge.com/en/news/285124185.md)
*2026-05-04T21:11:00.000Z*
> Evolus, Inc. reported a 6.7% year-over-year revenue increase to $73.14M for Q1 2026, with a narrowed net loss of $10.67M

### [Evolus | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 73.14 M](https://longbridge.com/en/news/285113724.md)
*2026-05-04T20:08:46.000Z*